Страница 15 из 18
34. Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response / S. Branford, R. Lawrence, A. Grigg et al. // ASH A
35. Иматиниб (Imatinib): инструкция, применение и формула. РЕГИСТР ЛЕКАРСТВЕННЫХ СРЕДСТВ РОССИИ 2007 [cited 2015 15.04.2015]; Available from: http://www.rlsnet.ru/m
36. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia / A. Hochhaus, R. A. Larson, F. Guilhot et al. // The New England journal of medicine. – 2017. – Vol. 376, № 10. – P. 917–927.
37. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants / R. Hehlma
38. Шухов, О. А. Молекулярная и цитогенетическая характеристика Ph-позитивного клона у больных хроническим миелолейкозом при длительном воздействии ингибиторов тирозинкиназ. Автореф. дисс. канд мед наук. ФГБУ Гематологический научный центр МЗ РФ.Vol. PhD / О. А. Шухов // Москва. – 2015. – 26 с.
39. Griffin, J. D., Weisberg, E. L. Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia / J. D. Griffin, E. L. Weisberg // Blood. – 2005. – Vol. 106, № 11. – P. 694.
40. Drug evaluation: Nilotinib – a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond / E. Jabbour, J. Cortes, F. Giles et al. // IDrugs. – 2007. – Vol. 10, № 7. – P. 468–79.
41. Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants / S. Redaelli, R. Piazza, R. Rostagno et al. // Journal of Clinical Oncology. – 2009. – Vol. 27, № 3. – P. 469–471.
42. Тасигна® (Tasigna). Инструкция по применению, противопоказания, состав и цена. РЕГИСТР ЛЕКАРСТВЕННЫХ СРЕДСТВ РОССИИ 2014 [cited 2015 15.04.2015]; Available from: http://www.rlsnet.ru/tn_index_id_39736.htm.
43. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia / K. Porkka, P. Koskenvesa, T. Lundán et al. // Blood. – 2008. – Vol. 112, № 4. – P. 1005–1012.
44. Спрайсел® (Sprycel®) Инструкция по применению, противопоказания, состав и цена. Справочник лекарств РЛС® 2015 17.10.2012 [cited 01.01.2015 01.01.]; Available from: http://www.rlsnet.ru/tn_index_id_38851.htm#pokazaniya-preparata-sprajsel®.
45. Описание лекарственного препарата БОСУЛИФ (BOSULIF). Справочник лекарственных средств Видаль 2015 2014; Available from: http://www.vidal.ru/drugs/bosulif__43441.
46. Бозутиниб (Bosutinibum) – описание вещества, инструкция… – РЛС. 2018 [cited 2018 29.04.2018]; Available from: https://www.rlsnet.ru/m
47. Инструкция по медицинскому применению лекарственного препарата Айклусиг. [cited 2022 07.05.2022]; Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=dcc203ed-3a4b-483b-b1be-9b5e94b76a17&t=.
48. Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase / F. Castagnetti, F. Pane, G. Rosti et al. // Frontiers in oncology. – 2021. – Vol. 11. – P. 642005–642005.
49. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial / J. E. Cortes, D. W. Kim, J. Pinilla-Ibarz et al. // Blood. – 2018. – Vol. 132, № 4. – P. 393–404.
50. ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML–CP) / T. P. Hughes, A. Hochhaus, G. Saglio et al. // ASH A
51. Hochhaus, A., Shah, N. P., Cortes, J. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML–CP): DASISION 3-year follow-up / A. Hochhaus, N. P. Shah, J. Cortes // Blood. – 2012. – Vol. 119, № 5. – P. 1123–1129.
52. Wei, G., Rafiyath, S., Liu, D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib / G. Wei, S. Rafiyath, D. Liu // Journal of Hematology & Oncology. – 2010. – Vol. 3, № 1. – P. 47.
53. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial / J. E. Cortes, C. Gambacorti-Passerini, M. W. Deininger et al. // J Clin Oncol. – 2018. – Vol. 36, № 3. – P. 231–237.
54. ENESTnd 5-Year Follow-Up: Continued Benefit of Frontline Nilotinib vs Imatinib in Patients With CML in Chronic Phase / T. Hughes, Le Coutre, P, Jootar et al. // Haematologica. – 2014. – Vol. 99, №Suppl.1. – P. Abstract S677.
55. Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML–CP): Long-Term Follow-Up (f/u) of ENESTnd / R. A. Larson, D-W. Kim, S. Issaragrisil et al. // Blood. – 2014. – Vol. 124, № 21. – P. 4541.
56. Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML–CP) Trial (DASISION, CA180–056) / J. Cortes, G. Saglio, M. Baccarani et al. // Blood. – 2014. – Vol. 124, № 21. – P. 152.
57. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) / E. Jabbour, H. M. Kantarjian, G. Saglio et al. // Blood. – 2013. – Vol. 123, № 4. – P. 494–500.
58. Expanding Nilotinib Access in Clinical Trials (ENACT) / F. E. Nicolini, A. Turkina, Z.-X. Shen et al. // Cancer. – 2012. – Vol. 118, № 1. – P. 118–126.
59. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy / A. Hochhaus, H. M. Kantarjian, M. Baccarani et al. // Blood. – 2007. – Vol. 109, № 6. – P. 2303–2309.
60. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML–CP) with resistance or intolerance to imatinib (START-C) / M. J. Mauro, M. Baccarani, F. Cervantes // Journal of Clinical Oncology. – 2008. – Vol. 26, № 15S (May 20 Supplement). – P. 7009.
61. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or – intolerant chronic myeloid leukemia in blast crisis / J. Cortes, P. Rousselot, D.-W. Kim et al. // Blood. – 2007. – Vol. 109, № 8. – P. 3207–3213.
62. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or – intolerant chronic myeloid leukemia in accelerated phase / F. Guilhot, J. Apperley, D.-W. Kim et al. // Blood. – 2007. – Vol. 109, № 10. – P. 4143–4150.
63. A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 'START-A' Study / F. Guilhot, J. F. Apperley, N. Shah et al. // ASH A
64. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib / J. E. Cortes, H. M. Kantarjian, T. H. Brümmendorf et al. // Blood. – 2011. – Vol. 118, № 17. – P. 4567–4576.
65. Tefferi, A., Letendre, L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia / A. Tefferi, L. Letendre // American Journal of Hematology. – 2011. – Vol. 86, № 7. – P. 610–611.
66. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors / P. Valent, E. Hadzijusufovic, G.-H. Schernthaner et al. // Blood. – 2014. – Vol. 125, № 6. – P. 901–906.